- Title
- Suboptimal Use of Cardioprotective Medications in Patients With a History of Cancer
- Creator
- Untaru, Rossana; Chen, Dongqing; Ngo, Doan T. M.; Kelly, Conagh; May, Austin; Collins, Nicholas J.; Leitch, James; Attia, John R.; Proeitto, Anthony M.; Boyle, Andrew J.; Sverdlov, Aaron L.
- Relation
- JACC: CardioOncology Vol. 2, Issue 2, p. 312-315
- Publisher Link
- http://dx.doi.org/10.1016/j.jaccao.2020.05.010
- Publisher
- American College of Cardiology
- Resource Type
- journal article
- Date
- 2020
- Description
- Modern cancer therapies have led to improved survival rates for many cancers. Rates of cardiovascular diseases (CVD) and risk factors are increased in cancer patients and survivors compared with the general population, and CVD has emerged as a leading cause of long-term morbidity and mortality in this population (1). Cardioprotective medications, including statins, angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), beta-blockers, and antiplatelet therapies remain cornerstones of primary and secondary CVD prevention. However, data regarding the use of cardioprotective medications among cancer patients and survivors have been inconsistent.
- Subject
- adult; cancer; patient; medical history; SDG 3; Sustainable Development Goals
- Identifier
- http://hdl.handle.net/1959.13/1445716
- Identifier
- uon:42651
- Identifier
- ISSN:2666-0873
- Rights
- © 2020 THE AUTHORS. PUBLISHED BY ELSEVIER ON BEHALF OF THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION. THIS IS AN OPEN ACCESS ARTICLE UNDER THE CC BY-NC-ND LICENSE (http://creativecommons.org/licenses/by-nc-nd).
- Language
- eng
- Full Text
- Reviewed
- Hits: 3303
- Visitors: 3454
- Downloads: 181
| Thumbnail | File | Description | Size | Format | |||
|---|---|---|---|---|---|---|---|
| View Details Download | ATTACHMENT02 | Publisher version (open access) | 107 KB | Adobe Acrobat PDF | View Details Download |